ACY001, bone marrow-derived hematopoietic stem cells for coronary artery occlusions

ACY001 are autologous, bone marrow-derived hemangioblast stem cells. Arteriocyte has successfully completed its Phase I clinical trial (SEACOAST I) to treat chronic coronary ischemia with ACY001, delivered via a catheter; no adverse events were reported. SEACOAST II, a planned Phase II efficacy trial, is under development.